Matrix metalloproteinase inhibitors

Details Matrix metalloproteinase inhibitors Matrix metalloproteinase inhibitors

2004-09-10

2009-10-13

Keys, Rosalynd (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S416000, C544S296000, C544S310000, C548S453000, C548S472000, C560S180000, C562S430000, C562S450000

Reexamination Certificate

active

07601729

ABSTRACT:
Compounds of Formula (I):wherein:A represents bond, C1-6alkyl or CH═CH—C1-4alkyl;B represents bond, O, S, SO, SO2, CO, CR7R8, CO2R14, CONR14R15, N(COR14)(COR15), N(SO2R14)(COR15) or NR14R15;D represents bond, or C1-6alkyl;E represents substituted aryl or substituted or unsubstituted heteroaryl;Q represents an optionally substituted 5- or 6-membered aryl or heteroaryl ring;X represents O, S, SO, SO2, CO, CNR5, CNOR5, CNNR5R6, NR11or CR7R8;Y represents CR5OR11, CR5SR11, NOR5, CR5NR6R11, SO, SO2, CO, CNR5, CNOR5or CS;R1and R1′each independently represents H, C1-6alkyl or C1-4alkylaryl;R2represents CO2R12, CH2OR12or CONR12R13, CONR12OR13, NR12COR13, SR12, PO(OH)2, PONHR12or SONHR12;R3represents H, C1-6alkyl or C1-4alkylaryl;R4represents optionally substituted aryl or heteroaryl;Z represents a bond, CH2, O, S, SO, SO2, NR5, OCR5R6, CR9R10O or Z, R4and Q together form an optionally substituted fused tricyclic group;R5and R6each independently represent H, C1-6alkyl or C1-4alkylaryl;R7and R8each independently represent H, halo, C1-6alkyl or C1-4alkylaryl;R9and R10each independently represents H, C1-6alkyl optionally substituted by halo, cyano, OR11or NR6R11, C1-4alkylaryl optionally substituted by halo, cyano, OR11 or NR6R11, OR11or, together with the N to which they are attached, R9and R10form a heterocyclic group:R11represents H, C1-6alkyl, C1-4alkylaryl or COR5;R12and R13each independently represent H, C1-3alkyl, C1-3alkylaryl or C1-3alkylheteroaryl or, together with the functionality to which they are attached, R12and R13form a heterocyclic group:R14and R15each independently represent H, C1-6alkyl, C1-4alkylaryl or C1-4alkylheteroaryl or together with the functionality to which they are attached R14and R15form a heterocyclic or fused heterocyclic group; and physiologically functional derivatives thereof, corresponding processes for preparation, pharmaceutical formulations containing them and their use as inhibitors of matrix metallproteinase enzymes (MMPs).

REFERENCES:
patent: 7250439 (2007-07-01), Gaines et al.
patent: 7375248 (2008-05-01), Holmes et al.
patent: 7476759 (2009-01-01), Holmes et al.
patent: WO 97/43238 (1997-11-01), None
patent: WO 02/083642 (2002-10-01), None
patent: WO2004/012663 (2004-02-01), None
Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. McGraw Hill Medical Publishing Division. 2001 p. 3.
M.Daheshia. Therapeutic inhibition of matrix metalloproteinases for the treatment of chronic obstructive pulmonary disease (COPD). Current Medical Research and Opinion, vol. 21, issue 4, pp. 587-593,2005.
M.G.Belvisi and K.M. Bottomley. The role of MMPs in the pathophysiology of COPD: a therapeutic role for inhibitors of MMPs? Inflamm. Res., vol. 52. p. 95-100,2003.
Hashizume, H. “Synthesis and Biological Activity of New 3-Hydroxy-3-Methylglutaryl-CoA-Synthase Inhibitors”, Chem. Pharm. Bull, vol. 42, No. 10, 1994, pp. 2097-2107.
Morales, R. et al. “Crystal Structures of Novel Non-Peptidic, Non-Zinc Chelating Inhibitors Bound to MMP-12”, Journal of Molecular Biology, London, GB, vol. 341, No. 4, Aug. 20, 2004, pp. 1063-1076.
Natchus, M.G. et al. “Development of New Carboxylic Acid-Based MMP Inhibitors Derived from Functionalized Propargylglycines”, Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 44, 2001, pp. 1060-1071.
Brinckerhoff et al., “Matrix Metalloproteinases: A Tail of A Frog That Became A Prince”, Nature Rev. Mol. Cell. Biol., 3, 2002, 207-14.
Brinckerhoff, “Joint Destruction in Arthritis: Metalloproteinases In The Spotlight”, Arthritis & Rheumatism, 34, 1991, 1073-5.
Belvisi et al., “The Role of Matrix Metalloproteinases (MMPs) In The Pathophysiology Of Chronic Obstructive Pulmonary Disease (COPD): A Therapeutic Role For Inhibitors of MMPs?”, Inflamm. Res., 52, 2003, 95-100.
Lanone et al., “Overlapping Enzyme-Specific Contributions Of Matrix Metalloproteinases-9 and 12 In IL-13-Induced Inflammation And Remodeling”, J. Clin. Investigation, 2003, 110, 4, 463-474.
Cox et al., “Matriz Metalloproteinase 9 And The Epidermal Growth Factor Signal Pathway In Operable Non-Small Cell Lung Cancer”, Clin. Cancer Res., 2000, 6, 6, 2349-55.
Galligioni et al., “Angiogenesis And Antiangiogenic Agents In Non-Small Cell Lung Cancer”, Lung Cancer, 2001, 34 Suppl. 4: 3-7.
Demedts et al., “Elevated MMP-12 Protein Levels In Induced Sputum from COPD Patients”, Thorax, 2006, 61: 196-201.
Russell et al., “Release and Activity of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 by Aveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease”, Am. J. Respir Cell Mol Biol, 2002, 26: 602-9.
Shapiro et al., “Cloning and Characterization of Unique Elastolytic Metalloproteinase Produced by Human Alveolar Macrophages”, J. Biol. CHem. 1993, 268: 23824-9.

Affiliated with

Also associated with

Rating

Matrix metalloproteinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Matrix metalloproteinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Matrix metalloproteinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4090018